Preview

Rational Pharmacotherapy in Cardiology

Advanced search

RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY

Full Text:

Abstract

Press Release of Bayer AG

About the Author

. Editorial

Russian Federation


References

1. Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Eng J Med 2017

2. Kearon C, Akl EA, Omelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest 2016;149:315-352.


For citation:


RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY. Rational Pharmacotherapy in Cardiology. 2017;13(2):284. (In Russ.)

Views: 121


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)